This online interactive survey investigated lipid-lowering approaches of French cardiologists in high- and very high-cardiovascular risk patients with hypercholesterolemia. Physicians assessed three hypothetical patients at three clinic visits, and selected the patients' cardiovascular risk category, target low-density lipoprotein cholesterol (LDL-C) and treatment. A total of 162 physicians completed 480 risk assessments; 58% of assessments correctly categorized the hypothetical patients. Most physicians chose the correct LDL-C target for one of the very high-risk patients, but higher-than-recommended targets were selected for the other very high-risk patient and the high-risk patient. Statins were the most commonly chosen treatment. French cardiologists often underestimate cardiovascular risk in patients with hypercholesterolemia, select a higher-than-recommended LDL-C target and prescribe less intensive treatment than that recommended by guidelines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402750 | PMC |
| http://dx.doi.org/10.57264/cer-2022-0181 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Percutaneous circulatory assistance in an interventional cardiology centre without on-site cardiac surgery.
Arch Cardiovasc Dis
December 2024
Department of Cardiology, Bastia Hospital Centre, 20604 Bastia, France.
Background: Percutaneous extracorporeal membrane oxygenation (ECMO) has been developed thanks to the progress in the field of cannulation, but still justifies the presence of an on-site cardiac resuscitation department. Corsica is a French island without an on-site cardiac surgery department.
Aim: To evaluate the percutaneous ECMO programme in Corsica.
Serum and urinary 5-hydroxyindolacetic acid, serotonin, chromogranin A, and NT-proBNP for the detection of carcinoid heart disease.
Eur J Endocrinol
November 2024
Service de Biochimie et biologie moléculaire, Hospices Civils de Lyon, Bron 69500, France.
Objective: The aim of this study was to evaluate the performance of different biomarkers for the detection of carcinoid heart disease (CHD) in neuroendocrine tumours (NETs), in particular serum 5-HIAA (s5HIAA).
Design: An explorative ancillary study of the French CrusoeNET cohort.
Methods: Patients managed in the Lyon-EURACAN Center of Excellence (CoE) were included when they were aged of at least 18 years, treated and followed for an advanced/metastatic ileum or lung NET, a NET irrespective of the primary location or from unknown primary location but with clinical CS, and/or elevation of urinary 5-HIAA (u5HIAA) twice greater than the upper limit of normal.
Clinical Outcomes According to Aortic Stenosis Management: Insights From Real-World Practice.
J Am Heart Assoc
November 2024
Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille Lille France.
Background: Real-world data regarding clinical outcomes according to aortic stenosis (AS) management are scarce. Therefore, we aimed to investigate long-term management across the spectrum of outpatients with AS.
Methods And Results: Between May 2016 and December 2017, consecutive outpatients with mild (peak aortic velocity, 2.
[Cardiovascular adverse effects of Bruton tyrosine kinase inhibitors: Pathophysiological mechanisms, screening, and management].
Bull Cancer
December 2024
Service d'hématologie clinique, CHU de Montpellier, Montpellier, France.
The covalent Bruton tyrosine kinase inhibitors (iBTKs) have profoundly transformed the management of B-cell lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL). These targeted therapies, with ibrutinib as the pioneer, have paved the way for significant improvement in the prognosis of many patients. With second-generation iBTKs such as acalabrutinib and zanubrutinib, the therapeutic landscape has expanded, offering potential new options for patients with CLL.
View Article and Find Full Text PDFReprint of: Scientific statement from the French neurovascular and cardiac societies for improved detection of atrial fibrillation after ischaemic stroke and transient ischaemic attack.
Rev Neurol (Paris)
December 2024
Hôpitaux de l'est parisien (Saint-Antoine-Tenon), AP-HP, Sorbonne Université, Inserm ICAN 1166, 184, Faubourg-Saint-Antoine, 75571 Paris cedex 12, France.
Atrial fibrillation (AF) is the primary cause of ischaemic stroke and transient ischaemic attack (TIA). AF is associated with a high risk of recurrence, which can be reduced using optimal prevention strategies, mainly anticoagulant therapy. The availability of effective prophylaxis justifies the need for a significant, coordinated and thorough transdisciplinary effort to screen for AF associated with stroke.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!